Clinical Practice Guidelines in Cardio-Oncology

Area of Science:

• Cardio-oncology
• Cardiotoxicity
• Cardiovascular complications of cancer therapy

Background:

• Cancer therapies including anthracyclines, trastuzumab, and radiotherapy can lead to left ventricular dysfunction and heart failure.
• Cardio-oncology consensus statements address definitions and management of these treatment-related cardiac issues.
• The natural history of treatment-induced heart failure is often heterogeneous.

Purpose of the Study:

• To summarize current consensus on recommended definitions and practices in cardio-oncology.
• To highlight key cancer therapies associated with cardiotoxicity.
• To outline current evidence regarding the prevention of treatment-related cardiac dysfunction.

Main Methods:

• Review of existing consensus statements and scientific literature in cardio-oncology.
• Identification of cancer therapies with known cardiotoxic potential.
• Evaluation of evidence for preventative strategies against cardiotoxicity.

Main Results:

• Cardiac function assessment by echocardiography is recommended before initiating cardiotoxic cancer therapies.
• Dexrazoxane demonstrates evidence for preventing cardiotoxicity under specific circumstances.
• Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and beta-blockers are not supported for unselected populations but may be considered in specific patient groups.

Conclusions:

• Standardized definitions and practices in cardio-oncology are crucial for managing cardiotoxicity.
• Proactive cardiac monitoring and targeted preventative strategies are essential for patients undergoing cardiotoxic cancer treatments.
• Personalized approaches to cardiotoxicity prevention are necessary, considering individual patient factors and specific therapies.